MDS/AML and TP53-mutated samples showed overall similar sensitivity to anti-CCRL2 ADC compared to de novo AML samples with erythroleukemia samples showing the highest sensitivity. The gene discussed is CCRL2; the disease is acute myeloid leukemia.